CoChat

Naltrexone and buprenorphine combination in the treatment of opioid dependence

Gerra, G., Fantoma, A., Zaimovic, A. · 2006 · Journal of Psychopharmacology

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Naltrexone treatment has demonstrated some advantages for special populations of heroin addicted individuals, but patients' compliance seems to be very poor, with a low adherence and low retention rate. Kappa-opioid system overdrive seems to contribute to opioid protracted abstinence syndrome, with dysphoria and psychosomatic symptoms during naltrexone treatment. The objective of this observational study was to determine the effectiveness of a functional k antagonist in improving naltrexone treatment outcome. A partial mu agonist/kappa antagonist (buprenorphine) and a mu antagonist (naltrexone) were combined during a 12 weeks protocol, theoretically leaving k antagonism as the major medication effect. Sixty patients were submitted to outpatient rapid detoxification utilizing buprenorphine and opioid antagonists. Starting on the fifth day, 30 patients (group A) received naltrexone alone. Alternatively, 30 patients (group B) received naltrexone (50mg oral dose) plus buprenorphine (4 mg sublingual) for the 12 weeks of the observational study. The endpoints of the study were: retention in treatment, negative urinalyses, changes in psychological symptoms (Symptom Checklist-90 Revised: SCL-90) and craving scores (visual analysis scale (VAS)). Thirty-four subjects (56.67%) completed the 12 weeks study. Twenty-one patients (35.0%) had all urine samples negative for opiates and cocaine. nine subjects (15.0%) had urine samples negative for cocaine and opiates for the last 4 weeks of the study. five subjects (8.3%) continued to use cocaine during the 12 weeks of the study. No significant change in pupillary diameter after buprenorphine administration was evidenced during clinical observations from baseline across the weekly measurements. Retention rates in group A (naltrexone) and group B (naltrexone + buprenorphine) at week 12 were respectively 40% (12 patients) and 73.33% (22 patients), with a significant difference in favour of group B (p= 0.018). Patients treated with naltrexone in combination with buprenorphine (B patients) showed a significantly lower rate of positive urines for morphine (4.45%) and cocaine metabolites (9.09%) than those treated with naltrexone alone (A) (25%, morphine; 33.33% cocaine) (p< 0.05; p< 0.05). Irritability, depression, tiredness, psychosomatic symptoms and craving scores decreased significantly less in Group A patients than in group B patients. The dysfunction of opioid system with kappa receptors hyper-activation provoked by heroin exposure, probably underlying dysphoric and psychosomatic symptoms during naltrexone treatment, seems to be counteracted, at least in part, by buprenorphine. The combination of buprenorphine and naltrexone may significantly improve the outcome of opioid antagonists treatment in terms of retention, negative urinalyses, and reduced dysphoria, mood symptoms and craving.

Overview

Integrity signals

Registry

Crossref · 10.1177/0269881106060835

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 53 references

Research works printed but not linked: 14

  1. Bachs L, 2003, Tidsskr Nor Laegeforen, 123, 1665
  2. Corbett A D, 1982, Nature, 291, 591
  3. Derogatatis L R, 1977, Administration, Scoring, and Procedure Manual – 1
  4. Giordano A L, 1990, J Pharmacol Exp Ther, 255, 536
  5. Grinenko A, 2003, Vestn Ross Akad Med Nauk, 10, 54
  6. 10.1111/j.1521-0391.2003.tb00552.x · doi:10.1111/j.1521-0391.2003.tb00552.x · Paper page
  7. Madoz-Gurpide A, 2004, Actas Esp Psiquiatr, 32, 199
  8. Mendelson J H, 1992, Neuropsychopharmacology, 7, 157
  9. O'Brien C P, 1986, NIDA Res Monogr, 67, 373
  10. Renault P F, 1981, NIDA Res Monogr, 28, 11
  11. Smiley P L, 1990, Journal of Pharmacology and Experimental Therapeutics, 253, 938
  12. Trujillo K A, 1989, National Institute on Drug Abuse Research Monograph, 95, 550
  13. van Brussel G H, 2001, Ned Tijdschr Geneeskd, 145, 1452
  14. Walsh S L, 1995, Journal of Pharmacology and Experimental Therapeutics, 274, 361

Cited by

See all 106

Metadata

Authors
Gerra, G., Fantoma, A., & Zaimovic, A.
Affiliations
  • National Department on Drug Policy, Rome, Italy
  • Addiction Research Centre, Ser.T., AUSL, Parma, Italy
Venue
Journal of Psychopharmacology
Published
2006-11
Volume
20
Issue
6
Pages
806-814
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2039166465
Cited by
106
References
53
Citations by year
2026: 6 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 6 · 2018: 8 · 2017: 6 · 2016: 2 · 2015: 7 · 2014: 8 · 2013: 7 · 2012: 12
FWCI
4.00
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords
opioid use disorder, heroin addiction, naltrexone, buprenorphine, combination pharmacotherapy, rapid detoxification, treatment retention, relapse, cocaine use, craving, pupil size, opioid antagonists, medication adherence, withdrawal syndrome, dysphoria, psychosomatic symptoms, urine drug testing, outpatient care
MeSH terms
Adult, Affect, Buprenorphine, Cocaine, Female, Heroin Dependence, Humans, Liver, Male, Naltrexone, Narcotic Antagonists, Opioid-Related Disorders, Psychiatric Status Rating Scales, Substance Abuse Detection, Survival Analysis, Cocaine-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Naltrexone and buprenorphine combination in the treatment of opioid dependence. https://app.cochat.ai/papers/10.1177/0269881106060835
The paper
Gerra, G., Fantoma, A., & Zaimovic, A. (2006). Naltrexone and buprenorphine combination in the treatment of opioid dependence. Journal of Psychopharmacology. https://doi.org/10.1177/0269881106060835

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.